ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients
Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
The EPO-TRAUMA study is a prospective, multi-centre, double-blind, phase III, randomised
controlled trial evaluating the efficacy of epoetin alfa compared to placebo in reducing
mortality and severe disability at six months in critically ill trauma patients.
2500 mechanically ventilated ICU patients admitted with a primary trauma diagnosis presenting
to the ICU will be recruited into the study from participating study centres in Australia,
New Zealand, Europe, and Saudi Arabia.
Phase:
Phase 3
Details
Lead Sponsor:
Australian and New Zealand Intensive Care Research Centre
Collaborators:
ANZICS Clinical Trials Group Health Research Board, Ireland Health Research Council, New Zealand Irish Critical Care Clinical Trials Network Medical Research Future Fund (MRFF) Medical Research Institute of New Zealand Monash University University College Dublin